# Does Tirzepatide Help Sleep Apnea? What Two Trials Found | Buy This GLP

See how tirzepatide changed sleep apnea severity in two phase 3 trials, who qualifies for Zepbound’s FDA-approved OSA indication, and what the trials say about PAP.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/do-glp1-drugs-help-sleep-apnea
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Does Tirzepatide Help Sleep Apnea? What Two Trials Found

Tirzepatide reduced breathing interruptions by 20 to 24 events an hour more than placebo in two trials of adults with obesity and moderate-to-severe obstructive sleep apnea.

Editorial profile: [Wesley Jenkins](https://buythisglp.com/authors/wesley-jenkins)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20265 min readUpdated November 2026

Fewer events per hour vs placebo at week 52 (95% CI) · Trial 1 · People not using PAP · 20.0 (14.2–25.8) · Trial 2 · People enrolled on PAP · 23.8 (17.9–29.6)

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   Two 52-week trials enrolled 469 adults with obesity and moderate-to-severe obstructive sleep apnea.
-   Compared with placebo, tirzepatide reduced breathing events by an estimated 20.0 per hour in one trial and 23.8 in the other.
-   The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The trials did not test whether tirzepatide could replace PAP.

The FDA approved Zepbound (tirzepatide) to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, alongside a reduced-calorie diet and increased physical activity [\[4\]](https://buythisglp.com/research/do-glp1-drugs-help-sleep-apnea#ref-4). The evidence below applies to this drug and population.

## What the trials found at 52 weeks

The two SURMOUNT-OSA trials compared tirzepatide with placebo. Trial 1 enrolled people who were unable or unwilling to use positive airway pressure (PAP). Trial 2 enrolled people already on PAP. They continued PAP during the trial, with a seven-day pause before assessment of the primary outcome. Participants in both groups received diet and physical activity counseling [\[1\]](https://buythisglp.com/research/do-glp1-drugs-help-sleep-apnea#ref-1) [\[4\]](https://buythisglp.com/research/do-glp1-drugs-help-sleep-apnea#ref-4).

The apnea-hypopnea index (AHI) counts episodes of stopped or reduced breathing per hour of sleep. Mean baseline AHI across the treatment and placebo groups was 51.5 in Trial 1 and 49.5 in Trial 2. At week 52, estimated AHI changes in Trial 1 were −25.3 with tirzepatide and −5.3 with placebo, a difference of −20.0 events per hour (95% confidence interval −25.8 to −14.2). In Trial 2, changes were −29.3 and −5.5, a difference of −23.8 (−29.6 to −17.9). Both comparisons had P < 0.001 [\[1\]](https://buythisglp.com/research/do-glp1-drugs-help-sleep-apnea#ref-1).

In a separate analysis, a [UK study of new sleep apnea diagnoses](https://buythisglp.com/research/glp1-sleep-apnea-treat-vs-prevent) found no clear reduction in incident OSA among adults with obesity and type 2 diabetes who started a GLP-1 receptor agonist compared with those who started a DPP-4 inhibitor. That study asked about prevention, while SURMOUNT-OSA measured changes in adults who already had OSA [\[2\]](https://buythisglp.com/research/do-glp1-drugs-help-sleep-apnea#ref-2).

## Dose and coverage

The trials began at 2.5 mg weekly and took up to 20 weeks to reach the maximum tolerated dose of 10 or 15 mg. Those are also the approved weekly maintenance doses for OSA [\[4\]](https://buythisglp.com/research/do-glp1-drugs-help-sleep-apnea#ref-4). If comparing self-pay offers, check [how quoted prices change with dose](https://buythisglp.com/research/nobody-says-what-happens-at-a-higher-dose) before using a starting price to estimate ongoing costs.

The [Medicare guide to Zepbound for OSA](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea) explains how the diagnosis, supporting records and plan rules affect coverage. Published cash prices may apply to different formulations or care packages, so check what the price includes.

## Follow-up for people who use PAP

A [survey of 24 European sleep centers](https://buythisglp.com/research/nobody-is-rechecking-your-cpap) found that PAP management and follow-up practices varied. It describes what centers reported, without measuring individual patient outcomes [\[3\]](https://buythisglp.com/research/do-glp1-drugs-help-sleep-apnea#ref-3).

The American Academy of Sleep Medicine says follow-up polysomnography or home sleep apnea testing may be appropriate after a clinically significant weight change [\[5\]](https://buythisglp.com/research/do-glp1-drugs-help-sleep-apnea#ref-5).

Ask your sleep clinician about PAP

The trials did not test permanent PAP withdrawal. If you use PAP, talk to your sleep clinician before changing settings or stopping therapy.

## Frequently asked

Is tirzepatide approved for sleep apnea?

The FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity.

What dose did the sleep apnea trials use?

The trials began at 2.5 mg weekly and increased the dose over up to 20 weeks to the maximum tolerated dose of 10 or 15 mg weekly. Each trial lasted 52 weeks.

How can I tell whether my sleep apnea has improved?

A sleep clinician can assess your symptoms and decide whether to repeat a laboratory sleep study or use a home sleep apnea test. The trials used polysomnography to measure the apnea-hypopnea index.

Does tirzepatide replace PAP therapy?

The trials did not test permanent PAP withdrawal. Participants who enrolled on PAP paused it before the main outcome assessment. Consult your sleep clinician before changing or stopping PAP therapy.

## Sources

1.  \[1\] Malhotra A, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity New England Journal of Medicine. [PMID 38912654](https://pubmed.ncbi.nlm.nih.gov/38912654/)
2.  \[2\] Khouri C, et al. (2026). Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study American Journal of Respiratory and Critical Care Medicine. [PMID 42745463](https://pubmed.ncbi.nlm.nih.gov/42745463/)
3.  \[3\] Testelmans D, Bonsignore MR, Pataka A, Fanfulla F, et al. (2026). Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network Pulmonology. [PMID 42639925](https://pubmed.ncbi.nlm.nih.gov/42639925/)
4.  \[4\] U.S. Food and Drug Administration (2026). Zepbound (tirzepatide) U.S. prescribing information FDA. [Source](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf)
5.  \[5\] Caples SM, et al. (2021). Use of polysomnography and home sleep apnea tests for the longitudinal management of obstructive sleep apnea in adults: an American Academy of Sleep Medicine clinical guidance statement Journal of Clinical Sleep Medicine. [PMID 33704050](https://pubmed.ncbi.nlm.nih.gov/33704050/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
